Dr. Peter Martin Discusses RBAC500: A Combination of Cytarabine with Rituximab and Bendamustine for Elderly Patients with Mantle Cell Lymphoma

healio

In an interview recorded during the 2016 American Society of Hematology Annual Meeting, Dr. Peter Martin discussed  results from a phase 2 trial where researchers from the Fondazione Italiana Linfomi found that the addition of intermediate-dose of cytarabine to the first line treatment of rituximab and bendamustine led to a 91% response rate in elderly people with mantle cell lymphoma. This chemotherapy combination is known as RBAC500.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s